Apolipoprotein B and Apolipoprotein A-I

Apolipoproteins are the structural and functional proteins of lipoprotein particles. Apolipoprotein B (apoB) is present in a single copy on each atherogenic particle—VLDL, IDL, LDL, and Lp(a)—so its concentration counts those particles directly, while apolipoprotein A-I (apoA-I) is the principal protein of HDL. Measuring these proteins offers a particle-based view of lipoprotein metabolism that complements cholesterol-mass measurements.

Definition

Apolipoprotein analysis is the immunochemical measurement of apolipoprotein B—one molecule of which is carried by each atherogenic VLDL, IDL, LDL, and Lp(a) particle—and apolipoprotein A-I, the main structural protein of HDL, used to characterise lipoprotein particle number and composition.

Scope

This topic covers what apoB and apoA-I represent, why one apoB molecule per atherogenic particle makes apoB a count of atherogenic particle number, the meaning of the apoB/apoA-I ratio, and how apoB compares with LDL and non-HDL cholesterol as a marker. It is a measurement and interpretation topic and does not provide clinical thresholds or treatment guidance.

Core questions

• Why does apolipoprotein B concentration reflect the number of atherogenic particles?
• How do apoB and apoA-I differ in the particles they mark?
• When does apoB add information beyond LDL or non-HDL cholesterol?
• What does the apoB/apoA-I ratio attempt to capture?

Key concepts

• Apolipoprotein B (one per atherogenic particle)
• Apolipoprotein A-I (principal HDL protein)
• Atherogenic particle number
• apoB/apoA-I ratio
• Discordance between apoB and LDL cholesterol
• Immunochemical apolipoprotein assays

Mechanisms

Each VLDL, IDL, LDL, and Lp(a) particle carries exactly one apolipoprotein B-100 molecule, so the plasma apoB concentration is a direct count of circulating atherogenic particles, independent of how much cholesterol each particle carries. Apolipoprotein A-I is the dominant protein of HDL and a structural participant in reverse cholesterol transport. Because the cholesterol content of LDL particles varies, apoB and LDL cholesterol can be discordant—two people with the same LDL cholesterol may carry different numbers of particles—which is the conceptual basis for measuring apoB. Apolipoproteins are measured immunochemically and can be standardised against reference materials.

Clinical relevance

Apolipoprotein B is used as a marker of atherogenic particle burden in cardiovascular risk assessment, particularly when triglycerides are high or LDL cholesterol is low and may underestimate particle number. This entry explains what the measurements represent at a conceptual level; it is reference material and does not provide diagnostic thresholds or therapy for individuals.

Evidence & guidelines

A meta-analysis comparing LDL cholesterol, non-HDL cholesterol, and apoB as risk markers, narrative syntheses of apoB particles, and major dyslipidaemia guidelines and laboratory consensus statements address the role of apoB relative to cholesterol-based measures. These are population-level and laboratory-practice documents rather than individualised recommendations.

History

The recognition that each atherogenic lipoprotein carries a single apoB molecule established apoB as a count of particle number rather than a measure of lipid mass. Standardised immunoassays made apoB and apoA-I measurable in routine laboratories, and accumulating comparative evidence and consensus work positioned apoB as a candidate marker where cholesterol-based measures may misclassify particle burden.

Debates

Apolipoprotein B versus cholesterol-based markers

Because particle number and cholesterol content can diverge, apoB may track atherogenic risk more faithfully than LDL or non-HDL cholesterol in some settings; how strongly to prefer apoB, and in whom, remains an active methodological and guideline discussion.

Key figures

• Allan Sniderman
• George Thanassoulis
• Brian Ference
• Michel Langlois

Seminal works

• sniderman-2011
• sniderman-2019

Frequently asked questions

Why is apolipoprotein B described as a particle count?

Each atherogenic lipoprotein particle—VLDL, IDL, LDL, and Lp(a)—carries exactly one apolipoprotein B molecule, so the total apoB concentration is proportional to the number of such particles, regardless of how much cholesterol each contains.

How does apolipoprotein A-I differ from apolipoprotein B?

Apolipoprotein A-I is the main protein of HDL and participates in reverse cholesterol transport, whereas apolipoprotein B marks the atherogenic, cholesterol-delivering particles; the two are sometimes expressed as the apoB/apoA-I ratio.